WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406462
CAS#: 1086639-59-9
Description: Y11 is a small molecule inhibitor targeting Y397 site of FAK. Y11 significantly and specifically decreased FAK autophosphorylation, directly bound to the N-terminal domain of FAK. In addition, Y11 decreased Y397-FAK autophosphorylation, inhibited viability and clonogenicity of colon SW620 and breast BT474 cancer cells and increased detachment and apoptosis in vitro. Moreover, Y11 significantly decreased tumor growth in the colon cancer cell mouse xenograft model. Finally, tumors from the Y11-treated mice demonstrated decreased Y397-FAK autophosphorylation and activation of poly (ADP ribose) polymerase and caspase-3.
MedKoo Cat#: 406462
Name: Y11
CAS#: 1086639-59-9
Chemical Formula: C8H17BrN4O
Exact Mass: 264.05857
Molecular Weight: 265.15078
Elemental Analysis: C, 36.24; H, 6.46; Br, 30.14; N, 21.13; O, 6.03
Y11, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: Y11; Y-11; Y 11
IUPAC/Chemical Name: (3r,5r,7r)-1-(2-hydroxyethyl)-1,3,5,7-tetraazaadamantan-1-ium bromide
InChi Key: HBPXFHNNLMCUPA-UHFFFAOYSA-M
InChi Code: InChI=1S/C8H17N4O.BrH/c13-2-1-12-6-9-3-10(7-12)5-11(4-9)8-12;/h13H,1-8H2;1H/q+1;/p-1
SMILES Code: OCC[N+]12C[N@]3C[N@](C2)C[N@](C3)C1.[Br-]
The following data is based on the product molecular weight 265.15078 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1. McLaughlin, Mark; Hazlehurst, Lori; Jain, Priyesh; Emmons, Michael F.; Gebhard, Anthony W.; Nair, Rajesh R. Preparation of peptides as integrin interaction inhibitors for the treatment of cancer. PCT Int. Appl. (2013), WO 2013170066 A1 20131114.